Tony is an experienced biotech CEO with a track record leading and building organizations across multiple scientific disciplines, therapeutic areas and stages of drug development. He most recently was president and CEO of Scholar Rock. Prior to that, he was president and CEO of TarisBio, president and COO of The Medicines Company, and the head of global commercial at Biogen.
Eddine Saiah, PhD
Dr. Saiah has over 25 years of experience heading drug discovery, preclinical and early development in large pharmaceutical and small biotech companies. He was most recently CSO at Navitor Pharmaceuticals where he led the company’s research and early development platform. Earlier in his career, Dr. Saiah held a series of leadership roles in drug discovery at Pfizer and Wyeth. He holds a Ph.D. in chemistry from Paris Sorbonne-Pierre and Marie Curie University and conducted postdoctoral studies at the Mayo Clinic.
Kevin Sprott, PhD
Kevin has over 20 years experience as a medicinal chemist leading projects and companies up and through clinical study. Prior to joining Stablix, Kevin provided his expertise to companies such as Syros, Verastem, Ironwood, and Millennium. Kevin and his teams have delivered 9 development candidates in diverse therapeutic areas, including oncology, immunology and pain.
Brian Bowman, PhD
SVP of Biology, Co-Founder
Brian has over 20 years of research experience as a protein biochemist, biophysicist, and molecular biologist. He's passionate about creating and developing innovative technologies and novel drug discovery platforms while building successful companies. Prior to Stablix, Brian was a co-founder of WarpDrive Bio and LifeMine Therapeutics and Head of Target Discovery at Inzen Therapeutics.
Scott Kanner, PhD
Associate Director of Platform Sciences, Co-Founder
Scott is driven by targeting common vulnerabilities in disease, with over 10 years of research experience across areas of pharmacology, physiology, cell biology, molecular biology, and protein engineering. He is co-inventor of the company’s foundational platform and heads the research and development of platform technologies at Stablix. As a training physician-scientist at the Medical Scientist Training Program (MSTP) at Columbia University’s Vagelos College of Physicians & Surgeons, Scott received his PhD in Neuroscience and the NIH National Research Service Award.
Uddhav Shigdel, PhD
Director, Biomolecular Sciences
Uddhav is passionate about drugging the undruggable. He has managed and established teams and laboratory capabilities for chemical synthesis, protein bioscience, protein complex crystallography, biochemical and biophysical assays as a founding scientist in three biotech startups. Notably, he designed first generation compounds for KRAS(G12C)-Cyclophilin A “Tri-Complex” inhibitors at WarpDrive Bio, currently the only compounds in clinical development that inhibit the active form of KRAS(G12C).
Yukie Takabatake, PhD
Associate Director, Cellular Biology
Yukie thrives being at the forefront of science in early-stage biotech companies. She is principal scientist in the biology team, leading efforts on assay development and throughput. Prior to Stablix, Yukie was a principal scientist at Yesse Technologies, Inc., where she ran the bioassay development team aimed at digitizing the sense of smell. She received her PhD in Biomedical Sciences from the Icahn School of Medicine at Mount Sinai and has unique translational expertise in oncology, neuroscience and olfaction research.